Pacira BioSciences, Inc. financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Pacira BioSciences, Inc. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	276	287	337	421	430	542	667	675	701	726
Cost of revenue	110	87.9	86.8	107	117	140	199	185	170	150
Gross profit	166	199	250	314	312	401	468	490	531	577
Research and development	45.7	57.3	55.7	72.1	59.4	55.5	84.8	76.3	81.6	117
Selling, general and administrative	153	161	177	201	194	199	255	269	294	369
Operating expenses	308	312	321	411
Operating income	-32	-24.9	15.9	10.5	46.4	89.9	60	87.7	-73.4	19.2
Interest expense	7.06	18	21.9	23.6	25.7	31.8	40	20.3	16.6	17.4
Interest income	1.32	4.08	6.5	7.38	4.63	0.9	4.54	11.4	19.7	22.7
Other non-operating income	-5.82	-17.5	-16.3	-21.2	-26.3	-33.5	-46.7	-26	10.3	-2.32
Pre-tax income	-37.8	-42.5	-0.43	-10.7	20.1	56.4	13.3	61.7	-63.1	16.9
Income tax	0.11	0.14	0.05	0.27	-125	14.4	-2.61	19.7	36.5	9.84
Net income	-37.9	-42.6	-0.47	-11	146	42	15.9	42	-99.6	7.03
EBITDA	-19.1	-11.1	29.1	30.1	66.3	118	152	163	5.41	110
EPS, basic	-1.02	-1.07	-0.01	-0.27	3.41	0.95	0.35	0.91	-2.15	0.16
EPS, diluted	-1.02	-1.07	-0.01	-0.27	3.33	0.92	0.34	0.89	-2.15	0.16
Shares, basic (weighted)	37.2	39.8	40.9	41.5	42.7	44.3	45.5	46.2	46.2	44.6
Shares, diluted (weighted)	37.2	39.8	40.9	41.5	43.7	45.6	46.5	52	46.2	45

Balance sheet

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	35.9	54.1	133	78.2	100	586	104	153	277	159
Short-term investments	137	257	251	214	422	70.8	185	125	208	79.9
Receivables	29.9	31.7	38	47.5	53	96.3	98.4	106	113	124
Inventory	31.3	41.4	48.6	58.3	64.7	98.6	96.1	104	125	153
Other current assets	9.28	6.69	7.95	10.8	12.3	14.8	15.2	21.5	21.9	32.6
Total current assets	243	391	478	409	652	866	498	510	745	548
Property, plant and equipment	101	107	109	105	137	188	184	174	167	141
Lease right-of-use assets			0	38.1	74.5	76.4	70.9	61	49.2	41.8
Goodwill	46.7	55.2	62	99.5	99.5	145	163	163	0	20.2
Intangible assets	0		0	104	96.5	624	541	483	426	368
Long-term investments	0	60	25.9	64.8	95.5	0	37.2	2.41	0
Other non-current assets	0.62	0.83	0.66
Total assets	391	628	689	831	1,275	2,075	1,681	1,574	1,554	1,265
Accounts payable	7.51	14.7	14.4	12.8	10.4	10.5	15.2	15.7	19.1	15.2
Accrued liabilities	36.7	41.1	45.9	70.4	71	128	89.8	64.2	80.1	95.6
Deferred revenue	0.6	0.1	0
Short-term debt	119								202	0
Total current liabilities	44.8	56.2	60.7	108	253	521	148	97.4	310	121
Long-term debt									384	372
Lease liabilities			0	40.9	71	71.7	64.8	54.8	44.6	36.2
Other non-current liabilities	18.9	16.5	16.9	1.5	3.83	20	9.67	13.6	16.8	20.6
Total liabilities	172	349	368	476	655	1,345	906	704	775	572
Total debt	109						689	522	585	372
Paid-in capital	565	669	710	754	873	942	924	977	1,009	1,065
Retained earnings	-346	-389	-388	-399	-254	-212	-149	-107	-206	-199
Treasury stock								0	-25.1	-177
Other comprehensive income	-0.03	-0.45	-0.28	0.32	0.32	0.17	-0.38	0.25	0.34	4.33
Shareholders' equity	219	279	321	355	620	730	775	870	778	693
Total equity	219	279	321	355	620	730	775	870	778	693
Total liabilities and equity	391	628	689	831	1,275	2,075	1,681	1,574	1,554	1,265
Shares outstanding	37.5	40.7	41.2	41.9	43.6	44.7	45.9	46.5	46.2	41.1

Cash flow statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	-37.9	-42.6	-0.47	-11	146	42	15.9	42	-99.6	7.03
Depreciation and amortization	12.9	13.8	13.2	19.6	19.9	28.5	91.5	75.6	78.8	91
Stock-based compensation	31.2	31.6	31.7	33.7	39.9	42.2	48.1	47.9	51.2	57.5
Deferred income tax		0	0	-1.83	-127	10.9	-7.95	15.6	20.6	6.48
Change in receivables	-4.08	-1.72	-6	-8.52	-5.52	-10.4	-2.08	-7.16	-7.75	-10.7
Change in inventory	30.4	-10.1	-7.16	-8.03	-6.35	-4.47	2.49	-8.29	-20.9	-27.6
Change in payables	-0.35	5.71	-0.57	-1.82	-3.31	-10.3	6.27	0.92	3.08	-5.6
Cash from operations	33.5	17.8	48.9	70.5	77	126	145	155	189	152
Capital expenditures	-24.7	-19.3	-14.5	-10.2	-37.8	-45.9	-30.1	-15.2	-10.6	-15.3
Acquisitions		0	0	-118	0	-420	0	0	0	-16.7
Purchases of investments	-193	-503	-363	-318	-547	-611	-388	-138	-252	-141
Sales and maturities of investments	172	322	405	319	308	1,069
Cash from investing	-61.8	-224	20.6	-128	-278	-20.8	-225	77.5	-83.3	99.5
Debt issued	-0
Stock issued	5.77	6.78	7.17	8.47	45.2	23.8	24.4	1.94	0	0.5
Share buybacks							0	0	-25	-148
Cash from financing	7.26	224	8.95	3.67	222	381	-402	-183	17.4	-370
Exchange rate effect								0	0	-0.08
Net change in cash			78.4	-54.3	21.7	486	-481	49.2	123	-118
Free cash flow	8.74	-1.48	34.4	60.4	39.2	79.9	115	139	179	137
Interest paid	3.85	6.9	8.21	8.2	7.21	7	33.3	27.6	15.4	15.2
Income taxes paid	0.25	0.13	0.13	0.86	2.42	3.22	7.4	4.4	11	9.01

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $25.12 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	79.2%	Gross profit / revenue.
Operating margin	2.7%	Operating income / revenue.
EBITDA margin	10.2%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	2.4%	Pre-tax income / revenue.
Net margin	2.0%	Net income / revenue.
FCF margin	24.1%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	25.2%	Cash from operations / revenue.
Effective tax rate	17.1%	Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)	2.2%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	1.2%	Net income / average total assets.
Return on invested capital (ROIC)	2.0%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue	16.3%	Research and development expense / revenue.
SG&A / revenue	50.8%	Selling, general and administrative expense / revenue.
Stock-based pay / revenue	7.5%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	1.1%	Capital expenditures / revenue.
D&A / revenue	7.6%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	3.6%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	2.9%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	11.1%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	8.7%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	7.2%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	13.0%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating income CAGR, 3y	-31.6%	Compound annual growth of operating income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating income CAGR, 5y	-16.2%	Compound annual growth of operating income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EBITDA growth, 1y	1,936.0%	EBITDA vs the same period a year earlier. Only from a positive base.
EBITDA CAGR, 3y	-10.1%	Compound annual growth of ebitda over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EBITDA CAGR, 5y	10.7%	Compound annual growth of ebitda over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Net income CAGR, 3y	-23.8%	Compound annual growth of net income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Net income CAGR, 5y	-45.4%	Compound annual growth of net income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EPS CAGR, 3y	-22.2%	Compound annual growth of eps over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EPS CAGR, 5y	-45.5%	Compound annual growth of eps over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y	-19.7%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y	1.5%	Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow CAGR, 5y	14.6%	Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Free cash flow growth, 1y	-23.5%	Free cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow CAGR, 3y	5.9%	Compound annual growth of free cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Free cash flow CAGR, 5y	28.4%	Compound annual growth of free cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y	-11.0%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	-3.7%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	2.3%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	-18.6%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	-9.0%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	-0.2%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	-2.6%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	-1.1%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	0.6%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	5.04x	Current assets / current liabilities.
Quick ratio	3.14x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	2.06x	(Cash + short-term investments) / current liabilities.
Debt / equity	0.54x	Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets	29.2%	Total debt / total assets.
Liabilities / assets	46.0%	Total liabilities / total assets.
Net debt	$112.1M	Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA	1.47x	Net debt / EBITDA (twelve months), when EBITDA is positive.
Interest coverage	1.28x	Operating income / interest expense.
Working capital	$493.2M	Current assets - current liabilities.
Goodwill and intangibles / assets	24.5%	(Goodwill + intangible assets) / total assets.
Tangible book value	$366.9M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.60x	Revenue / average total assets.
Fixed asset turnover	5.73x	Revenue / average property, plant and equipment.
Inventory turnover	1.15x	Cost of revenue / average inventory.
Days inventory	317 days	365 x average inventory / cost of revenue.
Receivables turnover	5.63x	Revenue / average receivables.
Days sales outstanding	65 days	365 x average receivables / revenue.
Days payables	41 days	365 x average accounts payable / cost of revenue.
Cash conversion cycle	340 days	Days inventory + days sales outstanding - days payables.
FCF conversion	1,226.0%	Free cash flow / net income, when net income is positive.
Capex / operating cash flow	4.3%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	$0.36	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$18.52	Revenue / diluted weighted shares.
FCF per share	$4.45	Free cash flow / diluted weighted shares.
Operating cash flow per share	$4.66	Cash from operations / diluted weighted shares.
Book value per share	$16.87	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$9.21	Tangible book value / shares outstanding.
Cash per share	$6.30	(Cash + short-term investments) / shares outstanding.
Buybacks / FCF	82.6%	Share buybacks / free cash flow, when free cash flow is positive.

Valuation

Metric	Value	How it is calculated
Market cap	$1.00B	Share price x shares outstanding.
Enterprise value	$1.11B	Market cap + total debt - cash - short-term investments.
P/E	68.4x	Market cap / net income. Only when net income is positive.
P/S	1.34x	Market cap / revenue.
P/B	1.49x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	2.73x	Market cap / tangible book value, when positive.
P/FCF	5.58x	Market cap / free cash flow. Only when free cash flow is positive.
P/OCF	5.34x	Market cap / cash from operations, when positive.
EV/Sales	1.49x	Enterprise value / revenue.
EV/EBIT	56.0x	Enterprise value / operating income, when both are positive.
EV/EBITDA	14.6x	Enterprise value / EBITDA, when both are positive.
EV/FCF	6.20x	Enterprise value / free cash flow, when both are positive.
FCF yield	17.9%	Free cash flow / market cap.
Earnings yield	1.5%	Net income / market cap (the inverse of P/E).
Shareholder yield	14.8%	(Dividends paid + share buybacks) / market cap.

What was Pacira BioSciences, Inc.'s revenue in fiscal 2025?

Pacira BioSciences, Inc. reported revenue of $726.4M for fiscal 2025, 3.6% higher than the year before.

Was Pacira BioSciences, Inc. profitable in fiscal 2025?

Yes. Net income was $7.0M, a net margin of 1%.

How much free cash flow did Pacira BioSciences, Inc. generate in fiscal 2025?

Cash from operations of $152.0M minus capital expenditures of $15.3M left free cash flow of $136.7M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to Pacira BioSciences, Inc.